Clinical Trial Update: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Brentuximab Vedotin in Chinese adults with CD30-positive cutaneous T-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: T-Cell Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2025-08-27